Back to results
US 2016/0252533 A1Published application
Diagnosis and treatment of autoimmune diseases
AssigneeDyax Corp.
InventorsDaniel J. Sexton, Burt Adelman, Andrew Nixon
Life of this patent
Estimating the term…
Abstract
Methods, kits and compositions for diagnosing and treating autoimmune diseases such as rheumatiodi arthritis, Crohn's disease, and ulcerative colitis.
Claims29
A method of diagnosing an autoimmune disease in a subject, the method comprising:
- providing a biological sample of a subject suspected of having the autoimmune disease;
- measuring a level of cleaved high molecular weight kininogen (HMWK) in the biological sample;
- and
- identifying the subject as having or at risk for the autoimmune disease, if the level of cleaved HMWK in the biosample is elevated as compared to a control sample.
1 more element
A method of monitoring development of an autoimmune disease in a subject, the method comprising:
- providing a first biological sample of a subject suspected of having the autoimmune disease at a first time point;
- measuring a first level of cleaved high molecular weight kininogen (HMWK) in the first biological sample;
- providing a second biological sample of the subject at a second time point subsequent to the first time point;
- measuring a second level of cleaved HMWK in the second biological sample;
- and
- assessing development of the autoimmune disease in the subject based on the change of the levels of cleaved HMWK in the first and second biological samples,
- wherein the second level of cleaved HMWK higher than the first level of cleaved HMWK indicates that the autoimmune disease progresses in the subject or the subject has developed or is at risk for developing the autoimmune disease.
4 more elements
A method of assessing the efficacy of a treatment for an autoimmune disease in a patient, the method comprising:
- providing multiple biological samples of a patient subjected to a treatment for an autoimmune disease during the course of the treatment;
- measuring the levels of high molecular weight kininogen (HMWK) in the multiple biological samples;
- and
- assessing the efficacy of the treatment in the patient based on the change of the levels of cleaved HMWK over the course of the treatment,
- wherein if the level of cleaved HMWK decreases during the course of the treatment, it indicates that the treatment is effective in the patient.
2 more elements
Dependencies are inferred from the claim text.